anti-ROR1 CAR T cells

anti-ROR1 CAR T cells are autologous or allogeneic T cells engineered to express a chimeric antigen receptor (CAR) that specifically recognizes receptor tyrosine kinase-like orphan receptor 1 (ROR1), a transmembrane protein aberrantly expressed on various hematologic and solid tumor cells, but generally absent from normal adult tissues. The engineered CAR T cells, using scFv sequences such as those derived from monoclonal antibodies like R12, R11, or cirmtuzumab, enable these T cells to specifically bind ROR1 and mediate targeted cytotoxicity against ROR1-positive tumor cells. Mechanism of action: The CAR, comprising an extracellular antigen-recognition domain (anti-ROR1 scFv), hinge region, transmembrane domain, one or more intracellular co-stimulatory domains (most commonly CD28 or 4-1BB), and a T-cell signaling domain (CD3ζ), redirects T-cell activity toward ROR1-expressing malignant cells, leading to their direct killing. anti-ROR1 CAR T cells are in early clinical and preclinical development for hematologic malignancies (e.g., chronic lymphocytic leukemia, mantle cell lymphoma) and solid tumors (e.g., breast cancer, lung cancer, other carcinomas).

Other names

ROR1-specific CAR-T cellsROR-1-specific CAR-T cellsROR 1-specific CAR-T cellsROR1 CAR T cell therapyROR-1 CAR T cell therapyROR 1 CAR T cell therapy